drugset / Trial / NCT00868634
Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer
Phase 3
Completed
600 enrolled
iOMEDICO AG
Arbeitsgemeinschaft fur Internistische Onkologie · collabArbeitskreis Klinische Studien · collabRoche Pharma AG · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of the trial is to detect the superiority of the triple combination of capecitabine, bevacizumab and vinorelbine versus the combination of capecitabine and bevacizumab in patients with metastatic breast cancer. 600 patients, 300 in each treatment group, are treated until progression of disease to determine PFS.
Timeline
- Start
- 2009-02
- Primary completion
- 2014-03
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |